Royalty Obligation and Deferred License Fees (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	10 years
WARF [Member]
Finite-Lived Intangible Assets [Line Items]
Amended license agreement amount	$ 295,000
Annual license maintenance fee	25,000
WARF [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	2.00%
WARF [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	4.00%
Advanced Cell Technology, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	20 years
Royalty rate on sale of products and services (in hundredths)	8.00%
Licensing fees paid	250,000
Maximum royalty payments	1,000,000
Advanced Cell Technology Inc., with Kirin Sublicense I [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	20 years
Royalty rate on sale of products and services (in hundredths)	5.00%
Licensing fees paid	200,000
Maximum royalty payments	600,000
Fees for sublicense (in hundredths)	20.00%
Advanced Cell Technology Inc., with Kirin Sublicense II [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	3.50%
Licensing fees paid	50,000
Fees for sublicense (in hundredths)	20.00%
Annual minimum royalty due	50,000
Reproductive Genetics Institute [Member]
Finite-Lived Intangible Assets [Line Items]
Common shares issued (in shares)	32,259
Common shares issued, market value	50,000
OncoCyte License From SBMRI [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	4.00%
Fees for sublicense (in hundredths)	20.00%
Fees for research use (in hundredths)	10.00%
Reduction in royalties (in hundredths)	50.00%
Reimbursement to SBMRI for cost incurred (in hundredths)	25.00%
Cell Cure Neurosciences License From Hadasit [Member]
Finite-Lived Intangible Assets [Line Items]
Amended license agreement amount	249,058
Fees for sublicense (in hundredths)	30.00%
Minimum percentage of sales of affiliates or sub licensees (in hundredths)	1.20%
Fees for research use (in hundredths)	5.00%
Sublicensing receipts for creditable milestone payments.	50,000,000
Cell Cure Neurosciences License From Hadasit [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Annual minimum royalty due	100,000
Teva License Agreement [Member] | Phase I Clinical [Member]
Finite-Lived Intangible Assets [Line Items]
Milestone payments	250,000
Teva License Agreement [Member] | Phase II Clinical [Member]
Finite-Lived Intangible Assets [Line Items]
Milestone payments	250,000
Teva License Agreement [Member] | Phase III Clinical [Member]
Finite-Lived Intangible Assets [Line Items]
Milestone payments	1,000,000
BioTime License For The University of Utah [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	3 years
Royalty rate on sale of products and services (in hundredths)	3.00%
Maximum royalty payments	2,500
Annual minimum royalty due	22,500
Fees for research use (in hundredths)	30.00%
Milestone payments	225,000
Minimum royalty amount each year and thereafter	30,000
Payment upon issuance of first five license	5,000
Reduction for any patent that have licensed two or more	2,500
Asterias License From University of California [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services (in hundredths)	1.00%
Fees for sublicense (in hundredths)	7.50%
Annual minimum royalty due	5,000
Reduction in royalties (in hundredths)	50.00%
Notice period to terminate agreement	60 days
Asterias Sublicense From Geron [Member]
Finite-Lived Intangible Assets [Line Items]
Amended license agreement amount	65,000
Annual license maintenance fee	$ 10,000
Fees for sublicense (in hundredths)	1.00%
Notice period to terminate agreement	90 days